市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Annovis Bio, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-1.9
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -5.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.88 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 14.69% |
| 机构持股比例 | 16.09% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Merit Financial Group, Llc | 30 Sep 2025 | 81,316 |
| Greenwich Wealth Management Llc | 30 Sep 2025 | 47,400 |
| Wescott Financial Advisory Group, Llc | 30 Sep 2025 | 41,607 |
| Lokken Investment Group Llc | 30 Sep 2025 | 29,248 |
| Sterling Investment Advisors, Ltd. | 30 Sep 2025 | 23,416 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合